TuberOus SClerosis registry to increase disease Awareness (TOSCA) – baseline data on 2093 patients by Kingswood, JC et al.
RESEARCH Open Access
TuberOus SClerosis registry to increase
disease Awareness (TOSCA) – baseline
data on 2093 patients
John C. Kingswood1*, Guillaume B. d’Augères2, Elena Belousova3, José C. Ferreira4, Tom Carter5, Ramon Castellana6,
Vincent Cottin7, Paolo Curatolo8, Maria Dahlin9, Petrus J. de Vries10, Martha Feucht11, Carla Fladrowski12,13,
Gabriella Gislimberti14, Christoph Hertzberg15, Sergiusz Jozwiak16, John A. Lawson17, Alfons Macaya18,
Rima Nabbout19, Finbar O’Callaghan20, Mirjana P. Benedik21, Jiong Qin22, Ruben Marques14, Valentin Sander23,
Matthias Sauter24, Yukitoshi Takahashi25, Renaud Touraine26, Sotiris Youroukos27, Bernard Zonnenberg28,
and Anna C. Jansen29 on behalf of TOSCA consortium and TOSCA investigators
Abstract
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant genetic disorder. Many gaps remain
in the understanding of TSC because of the complexity in clinical presentation. The TuberOus SClerosis registry to
increase disease Awareness (TOSCA) is an international disease registry designed to address knowledge gaps in the
natural history and management of TSC. Here, we present the baseline data of TOSCA cohort.
Methods: Patients of any age diagnosed with TSC, having a documented visit for TSC within the preceding
12 months, or newly diagnosed individuals were included. The registry includes a “core” section designed to
record detailed background information on each patient including disease manifestations, interventions, and
outcomes collected at baseline and updated annually. “Subsections” of the registry recorded additional data
related to specific features of TSC.
Results: Baseline “core” data from 2093 patients enrolled from 170 sites across 31 countries were available
at the cut-off date September 30, 2014. Median age of patients at enrollment was 13 years (range, 0–71)
and at diagnosis of TSC was 1 year (range, 0–69). The occurrence rates of major manifestations of TSC
included – cortical tubers (82.2%), subependymal nodules (78.2%), subependymal giant cell astrocytomas
(24.4%), renal angiomyolipomas (47.2%), lymphangioleiomyomatosis (6.9%), cardiac rhabdomyomas (34.3%),
facial angiofibromas (57.3%), forehead plaque (14.1%), ≥ 3 hypomelanotic macules (66.8%), and shagreen
patches (27.4%). Epilepsy was reported in 1748 (83.5%) patients, of which 1372 were diagnosed at ≤ 2 years
(78%). Intellectual disability was identified in 451 (54.9%) patients of those assessed. TSC-associated neuropsychiatric
disorders (TAND) were diagnosed late, and not evaluated in 30–50% of patients.
Conclusion: TOSCA is the largest clinical case series of TSC to date. It provided a detailed description of the disease
trajectory with increased awareness of various TSC manifestations. The rates of different features of TSC reported here
reflect the age range and referral patterns of clinics contributing patients to the cohort. Documentation of TAND
and LAM was poor. A widespread adoption of the international TSC assessment and treatment guidelines, including
use of the TAND Checklist, could improve surveillance. The registry provides valuable insights into the necessity for
monitoring, timing, and indications for the treatment of TSC.
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Background
Tuberous sclerosis complex (TSC) is a rare genetic
disorder characterized by the development of benign
tumors in several organs of the body [1]. The birth inci-
dence of the disorder is approximately 1 in 5800 individ-
uals [2]. TSC is caused by genetic mutations in either of
the TSC1 or TSC2 genes [3]. Based on routine diagnostic
techniques, a pathogenic mutation is detected in up to
85–90% of individuals with a clinical diagnosis of TSC
[1]. In the remaining 10–15% patients with ‘no mutation
identified’, next generation DNA sequencing (NGS), a
high-throughput sequencing, identified mosaic or intronic
mutations in TSC1 or TSC2 genes in a vast majority sug-
gesting that it is unlikely that a third TSC gene exists [4].
Mutations of TSC1 or TSC2 gene result in overactivation
of the mammalian target of rapamycin (mTOR) complex
1, a key intracellular regulator of cell growth and prolifera-
tion, resulting in the hamartomatous lesions found in
multiple organs [5, 6]. Recent research has helped us
understand the pathophysiology of TSC, which has led to
the use of mTOR inhibitors for the treatment of certain
manifestations of TSC including subependymal giant
cell astrocytomas (SEGAs) and renal angiomyolipomas
[7–10]. The recently revised guidelines for the surveil-
lance and management of TSC provided updated recom-
mendations for standard, optimal care for patients [10].
There is, however, still a lack of clarity with respect
to the natural history of many of the TSC manifesta-
tions, their variability, the age-related expression pat-
tern, and their prognostic roles. Gaps also exist in
understanding the rare symptoms and comorbidities of
TSC, the relationship between genotype and phenotype,
and the various interventions, treatments, and their
outcomes. An improved understanding of the natural
history of TSC is essential in order to evaluate the benefit-
risk ratio of any intervention accurately. TuberOus SCler-
osis registry to increase disease Awareness (TOSCA) was
established as a multicenter, international disease registry
with the specific aim to gather clinical data on this rare
disease in a systematic and longitudinal way. TOSCA con-
sists of a “core” dataset representing the diagnostic charac-
teristics and core associated clinical features, and “petal
projects” which represent detailed sub-projects focusing
on specific TSC manifestations. The results from the base-
line core data of the TOSCA cohort are reported here.
Methods
The study methods have been described in detail previ-
ously [11]. All patients gave informed consent. TOSCA
is a multicenter, international disease registry that was
designed to collect data on patients with TSC from
many countries worldwide. Patients of any age with a
diagnosis of TSC (definite, probable, or possible) and
with a documented clinical visit for TSC within the past
12 months or newly diagnosed with TSC were eligible.
The certainty of diagnosis was based on the 1998 revised
Gomez criteria.[12] The registry consists of a “core” sec-
tion and subsections or “petals”. The “core” section col-
lected general information on patients’ background
which included demographic data, family history, pre-
natal history, and disease features such as neurological
and neuropsychiatric, renal, cardiovascular, pulmonary,
dermatological, and others. This information was col-
lected at baseline and is being updated annually.
Subsections (“petals”) are being developed as research
projects to record in-depth data related to specific
disease manifestations. Pediatric and adult sites with
specialists in managing one or more aspects of TSC
were included in the registry. Patients will be followed
up for up to five years and an interim analysis will be
conducted every year.
Results
Overall findings
TOSCA recruited a total of 2223 patients from 170 cen-
ters in 31 countries (Fig. 1), over half of them (57%)
from neuropediatric/pediatric clinics (Fig. 2). At the cut-
off date September 30, 2014, complete baseline data
from 2093 patients (1009 male and 1084 female) were
available. Median age at inclusion in TOSCA was
13 years (range, 0–71). Patient distribution by age at in-
clusion in TOSCA is shown in Fig. 3 (≤18 years, 63.3%;
> 18 years, 36.7%). Median age at diagnosis of TSC was
1 year (range 0–69). TSC was diagnosed prenatally in
124 (5.9%) patients. Molecular testing had been per-
formed in 902 (43.1%) patients. TSC1 mutations were
identified in 19.7% of the patients and TSC2 in 63.3%
(Table 1). Only known pathogenic mutations as defined
in the Leiden Open Variation Database (LOVD) were
counted.[13] Five patients had both TSC1 and TSC2
mutations.
Neurological manifestations
Cortical tubers and subependymal nodules were the
most commonly reported neurological manifestations
(reported in 82.2 and 78.2% of patients, respectively). A
total of 510 (24.4%) patients had ever been diagnosed
with SEGA (Table 2). For TOSCA, a broad definition of
SEGA was adopted, based on the presence of a lesion
near the foramen of Monro without specific criteria for
size or growth. Median age at SEGA diagnosis was
8 years (range 0–51) (Additional file 1). SEGA was diag-
nosed before age 2 years in 132 (26.4%), before age
18 years in 278 (55.6%), and after age 18 years in 90
(18%) patients. SEGA was present at the time of recruit-
ment in TOSCA in 422 (82.7%) patients. Of these, 195
(46.2%) were bilateral and 155 (36.7%) showed growth
since the previous scan. Growth was reported in 10 out
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Fig. 1 Patients enrolled from different countries in TOSCA (N = 2223). *European countries include: Austria, Belgium, Czech Republic, Denmark,
Estonia, France, Germany, Greece, Italy, Latvia, Lithunia, Netherlands, Norway, Poland, Portugal, Romonia, Slovakia, Slovenia, Spain, and Sweden.
#Outside Europe include: Australia, Israel, Japan, Korea, Russia, South Africa, Mainland China, Hongkong, Macau, Taiwan, Thailand, and Turkey
Fig. 2 Distribution of TOSCA participants among different specialties (N = 2223)
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of 93 patients with SEGA diagnosed after age 18 years.
The median time between scans was 1 year (range 0–22).
In 207 out of the 510 patients with SEGA, a patho-
genic mutation was detected in TSC1 in 22 patients and
TSC2 in 185 patients. SEGA were bilateral in 18% and
growing in 4.5% of patients with mutations in TSC1
versus in 34 and 16% of patients with mutations in
TSC2. The majority (70.9%) of the patients with SEGA
were asymptomatic at the time of assessment. In symp-
tomatic patients, the most common symptoms/signs
were increase in seizure frequency (65 [15.4%]), behav-
ioral disturbances (50 [11.8%]), headache (34 [8.1%]),
and regression or loss of cognitive skills (31 [7.3]). A
total of 189 (9%) patients received treatment before
baseline visit. Median time from SEGA diagnosis to
treatment was less than 1 year (range 0–15). The most
common treatment modality was surgery (114 [60.3%]),
mTOR inhibitor (88 [46.6%]), and ventriculoperitoneal
shunt (21 [11.1%]), provided as monotherapy or in com-
bination with other treatments.
Epilepsy was reported in 1748 (83.5%) patients
(Table 2). The most common seizure type was focal
seizures (1169 [66.9%]). The median age at diagnosis of
focal seizures was 1 year. Most of the patients (73%)
were diagnosed at or before the age of 2 years. Of the
1144 patients who received treatment, 745 (65.1%) were
treated with gamma-aminobutyric acid (GABAergics [as
a single agent or in combination with another treatment
modality]). Additional treatment modalities as single
agents or in combination with other treatment modal-
ities included mTOR inhibitor (80 [7.0%]), surgery (80
[7.0%]), ketogenic diet (49 [4.3%]), vagal nerve stimula-
tion (45 [3.9%]), fructose derivatives (33 [2.9%]), and
adrenocorticotropic hormone (ACTH, 31 [2.7%]). Focal sei-
zures were controlled by treatment in 672 (58.7%) patients,
while not controlled in 411 (35.9%) patients. The next most
common seizure type reported was infantile spasms (679
[38.8%]). Of the 660 patients who received treatment for in-
fantile spasms, 517 (78.3%) were treated with GABAergics
and 118 (17.9%) with ACTH, either as monotherapy or in
combination with other therapies. Infantile spasms were
controlled by treatment in 471 (71.5%) patients, while not
controlled in 105 (15.9%) patients.
TSC-associated neuropsychiatric disorders (TAND)
Among the patients who were evaluated for TAND,
academic/scholastic difficulties were noted in 682
(57.8%) patients. Of the 822 (39.2%) patients who had
been evaluated using intelligent quotient (IQ)-type tests,
451 (54.9%) patients had mild to profound intellectual
disability. Autism spectrum disorder (ASD), attention
deficit hyperactivity disorder (ADHD), anxiety disorder,
and depressive disorder were reported in 20.7, 19.6, 9.1,
and 6.1% of patients excluding patients whose data was
not available. The mean (median [range]) age at diagnosis
of neuropsychiatric disorders were — ASD, 7.6 (5 [0–38]);
ADHD, 7.7 (6 [0–38]); anxiety, 17.8 (15 [0–50]); depres-
sion, 24.4 (21 [3–49]) years (Additional file 1). Neuro-
psychological skills were assessed in 510 patients of whom
281 (55%) patients had performance < 5th percentile. Pa-
tients who reported at least one behavioral problem were
745 (35.6%). Behavioral problems reported in > 10%
patients were sleep difficulties, impulsivity-overactivity,
severe aggression, anxiety, and mood swings. Missing data
of TAND features in the TOSCA population was high
(Table 3).
Fig. 3 Patient distribution by age for inclusion in TOSCA (N = 2093). Median age at consent was 13 years (range 0–71)
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Renal manifestations
Renal angiomyolipomas were reported in 987 (47.2%;
males, 42.5% and females, 57.5%) patients and diagnosed
at a mean age of 17.4 years (median age 13.0 years; range
0–67) (Table 2). The majority of angiomyolipomas (946
patients, 95.8%) recorded at baseline were diagnosed
prior to recruitment, most (792 patients, 83.7%) of
which were without any signs and symptoms at the time
of assessment. Of the patients with ongoing lesions, 793
(83.8%) had bilateral angiomyolipomas, 829 (87.6%) had
multiple lesions, 329 (34.8%) had angiomyolipoma
lesions > 3 cm in diameter, and 396 (41.9%) had both
multiple and bilateral renal angiomyolipomas. The most
common past medical history of signs/symptoms
reported included pain (51 [5.4%]), elevated blood pres-
sure (48 [5.1%]), impaired renal function (36 [3.8%]),
hemorrhage (47 [5%]), and microscopic hematuria (35
[3.7%]). Renal angiomyolipomas were treated in 274
(27.8%) patients. Most common mode of treatment
(monotherapy or in combination with other treatment
modalities) was embolization (126 [46%]) followed by
mTOR inhibitors (110 [40.1%]).
Among other renal features, multiple renal cysts were
the most frequent (22.8%) while polycystic kidneys
(3.5%), impaired renal function (non-angiomyolipoma
related; 2.1%), and renal malignancy (1.1%) were infre-
quently reported (Table 2).
Table 1 Baseline patient demographics and clinical
characteristics (N = 2093)
Characteristics Baseline data
Age at diagnosis of TSC,a years, median (range) 1.0 (0–69)
Gender, n (%)
Male 1009 (48.2)
Female 1084 (51.8)
Patients with molecular testing, n (%) 902 (43.1)
Genetic testingb, n (%c) 885 (98.1)
No mutation identified 125 (13.9)
TSC1 mutation 178 (19.7)
TSC2 mutation 571 (63.3)
Variation type, n (%)d
Pathogenic mutation 633 (93.8)
Variant of unknown significance 61 (9.0)
Time from TSC clinical diagnosis to molecular testing, months
Mean (SD) 79.6 (116.78)
Median (range) 22 (0–721)
Patients with prenatal diagnosis, n (%) 124 (5.9)
Biological mother/father evaluated for TSC, n
Mother 865
Father 753
TSC inherited from one parent, n
Total 290
Mother 168 (95 clinically)
Father 122 (56 clinically)
Patients with affected relatives, n (%)
Total 478 (22.8)
1 259 (12.4)
2 116 (5.5)
3 54 (2.6)
> 3 52 (2.5)
Patients with at least one blood relative participating
in TOSCA, n (%)
207 (9.9)
SD standard deviation, TSC tuberous sclerosis complex, TOSCA TuberOus
SClerosis registry to increase disease Awareness
aData available for 2054 patients; bInformation on the type of mutation was
missing for 6 patients; 5 patients had both TSC1 and TSC2 mutations;
cPercentages calculated considering the number of patients with molecular
testing as the denominator value. dThe count (n) includes 19 patients who had
both variation types
Table 2 Baseline manifestations of TSC reported in TOSCA
Manifestations of TSC Patients at baseline,
n (%)
Neurological
SEGA 510 (24.4)
Cortical tuber 1721 (82.2)
SEN 1636 (78.2)
Cerebral white matter radial migration lines 429 (20.5)
Renal
Renal angiomyolipoma 987 (47.2)
Multiple renal cysts 477 (22.8)
Polycystic kidneys 73 (3.5)
Impaired renal function 43 (2.1)
Renal malignancy 24 (1.1)
Pulmonary
Lymphangioleiomyomatosis 144 (6.9)
Cardiavascular
Cardiac rhabdomyoma 717 (34.3)
Dermatologic
≥ 3 hypomelanotic macules 1399 (66.8)
Facial angiofibroma 1199 (57.3)
Shagreen patch 573 (27.4)
Ungual or periungual fibromas 350 (16.7)
Forehead plaque 295 (14.1)
Confetti lesions 179 (8.6)
Ophthalmologic
Retinal hamartoma 294 (14.0)
Epilepsy 1748 (83.5)
SEGA subependymal giant cell astrocytoma, SEN subependymal nodule, TOSCA
TuberOus SClerosis registry to increase disease Awareness
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Pulmonary manifestations
Lymphangioleiomyomatosis (LAM) was reported in 144
(6.9%) patients of whom 142 (98.6%) were adults
>18 years (Table 2). Of these, 136 were females
(≤18 years, 2 [1.4%]; 18–40 years, 70 [51.4%]; > 40 years,
64 [47%]) and 8 were males. Mean age at diagnosis was
36.7 years (median age 35.0 years; range 9–61). Almost
all patients (142 of 144) were diagnosed with LAM when
they were > 18 years of age. LAM caused signs and/or
symptoms in 58 (40.3%) patients. The most common
symptom was dyspnea (69%), and lung collapse and/or
pneumothorax (44.8%). In the 46 patients who received
treatment, mTOR inhibitors (23 patients, 50%, alone or
in combination with other treatment modalities) was
most commonly used. Other treatment modalities in-
cluded surgery, chest tube, chylous fluid drainage, and
bronchodilators.
Cardiovascular manifestations
Cardiac rhabdomyomas, which were the most frequent
cardiovascular manifestations found in 717 (34.3%)
patients (Table 2). These were diagnosed at a mean age
of 3.1 years. Cardiac rhabdomyomas reported earlier and
were still present in 483 (67.4%) patients at the time of
Table 3 TSC-Associated Neuropsychiatric Disorders (TAND) features reported in TOSCA at baseline
TAND features Patients with manifestation, n/patients
with available data (%)
Patients with available
data, n/2093 (%)
Missing data,
n/2093 (%)
Behavioral difficulties
Overactivity 317 (20.7) 1533 (73.2) 560 (26.8)
Sleep difficulties 301 (19.5) 1540 (73.6) 553 (26.4)
Impulsivity 297 (19.4) 1533 (73.2) 560 (26.8)
Anxiety 205 (13.7) 1498 (71.6) 595 (28.4)
Mood swings 201 (13.4) 1499 (71.6) 594 (28.4)
Severe aggression 168 (10.8) 1559 (74.5) 534 (25.5)
Depression mood 124 (8.3) 1500 (71.7) 593 (28.3)
Self-injury 106 (6.8) 1555 (74.3) 538 (25.7)
Obsession 92 (6.1) 1505 (71.9) 588 (28.1)
Psychosis 34 (2.3) 1514 (72.3) 579 (27.7)
Hallucination 23 (1.5) 1512 (72.2) 581 (27.8)
Psychiatric disorders
ASD 291 (20.7) 1406 (67.1) 687 (32.8)
ADHD 260 (19.6) 1329 (63.4) 764 (36.5)
Anxiety 118 (9.1) 1294 (61.8) 799 (38.2)
Depression 80 (6.1) 1301 (62.1) 792 (37.8)
Intellectual Abilitya
Normal 371 (45.1) NA NA
Mild ID 232 (28.2) NA NA
Moderate ID 123 (15.0) NA NA
Severe ID 75 (9.1) NA NA
Profound ID 21 (2.6) NA NA
Academic difficulties
Patients ever had difficulties in academic performance 682 (57.8) 1179 (56.3) 914 (43.7)
Patients assessed for academic difficulties 332 (48.6% of those with reported difficulties) 332 (15.9) NA
Neuropsychological difficulties
Patients ever had any neuropsychological skill assessed 510 (40.1) 1270 (60.6) 823 (39.3)
Patients with performance < 5th percentile 281 (55% of those who had neuropsychological
assessment)
281 (13.4) NA
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, NA not applicable, TOSCA TuberOus SClerosis registry to increase disease Awareness,
TAND TSC-associated neuropsychiatric disorders, ID Intellectual Disability
aPatients with intellectual ability measured by intellectual quotient were available in 822 (39.3%) out of 834 patients. Intelligent ability was not measured in 752
(35.9%) patients
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assessment, resolved spontaneously in 208 (29%)
patients, and resolved after treatment in 24 (3.3%)
patients. Among other cardiovascular features,
arrhythmia/dysrhythmia and valve dysfunction were re-
ported in 5.6 and 2.9% of patients, respectively.
Aneurysm (1%) and coarctation of aorta (0.2%) were
rarely reported.
Dermatological and dental manifestations
The most frequently reported dermatological manifesta-
tions were facial angiofibromas (1199 [57.3%]). The me-
dian age at onset of facial angiofibroma was 6.0 years
(range 0–67). Approximately, one-third (32.8%) of the
patients had received treatment. Common treatment
modalities included laser therapy (49.1%), topical mTOR
inhibitors (23.2%) and systemic mTOR inhibitors
(21.1%) used alone or in combination with other treat-
ment modalities. Hypomelanotic macules (≥3) were
reported in 66.8% of patients (median age 1.0 year;
range, 0–67). Other dermatological manifestations
included shagreen patch (27.4%), ungual or peri-ungual
fibroma (16.7%), forehead plaque (14.1%), confetti
lesions (8.6%), and other dermatological conditions
(17.2%, angiomyolipoma [also known as a cutaneous
angiolipoleiomyoma], cafe au lait macule, poliosis, and
skin tags). Dental manifestations included randomly
distributed pits in dental enamel (98 [4.7%]) and gingival
fibromas (96 [4.6%]).
Ophthalmological manifestations
Retinal hamartomas, the most frequent ophthalmo-
logical manifestation, were reported in 294 (14%) pa-
tients, and diagnosed at a mean age of 8.3 years (median
age 5.0 years; range 0–50). These were symptomatic in
12.6% of patients. Symptoms included blurred vision,
constriction of visual field, and visual impairment.
Retinal achromic patch (53 [2.5%]) and other TSC-
related ophthalmological lesions (73 [3.5%]) were also
reported but less commonly.
Other manifestations
Liver hamartomas were reported in 190 (9.1%) patients,
with a higher frequency in female patients (73.7% of
those with liver hamartomas), and diagnosed at a mean
age of 23.3 years (median age 22 years; range 0–61).
Both ongoing liver hamartoma and angiomyolipomas
was reported in 168 patients.
Reproductive abnormalities were noted in a small
number of patients and included menstrual cycle dis-
orders (67 [6.2%]), amenorrhea (female patients >
11 years, 38 [3.5%]), abnormal onset of puberty (93
[4.4%]), other abnormal reproductive conditions (49
[2.3%]), abnormal hormone levels including prolactin
(21 [1%]), thyroid-stimulating hormone (145 [6.9%]),
follicle-stimulating hormone (37 [1.8%]), testosterone
(21 [1%]), and luteinizing hormone (35 [1.7%]).
Collectively, manifestations previously thought to be
rare were reported in 316 (15.1%) patients; bone scler-
otic foci in 87 patients, scoliosis in 46 patients, thyroid
adenoma in 15 patients, spleen angiomyolipoma in 5
patients, pancreatic neuroendocrine tumor in 5 patients,
and hemihypertrophy (abnormal growth on one side of
the body), calvarial sclerosis and thickening (each in 2
patients).
Co-morbidities were reported in 347 (16.6%) patients;
cardiovascular co-morbidities were the most frequent
(44 patients). Other less common comorbidities included
malignancies (15 patients), dyslipidemia (17 patients)
and diabetes (5 patients). Other features of TSC reported
were bone cysts (65 patients), non-renal hamartoma (ex-
cluding liver, 34 patients), and hamartomatous rectal
polyps (8 patients).
Manifestations of TSC across age groups in TOSCA
Participants
Figure 4 depicts a distinctive pattern to age-related
emergence and prevalence of TSC manifestations. Hypo-
melanotic macules, subependymal nodules, cortical tu-
bers and cardiac rhabdomyomas were reported from
age ≤ 2, (presumably as soon as they were looked for),
and their prevalence did not change. In contrast, the
prevalence of SEGAs and retinal hamartomas peaked in
childhood, and the prevalence of renal angiomyolipo-
mas, facial angiofibromas, forehead plaques and sha-
green patches went on increasing into adulthood.
However all these lesions were reported in a small
number of patients from age ≤ 2 years. In contrast, pul-
monary LAM and ungual fibromas presented later but
also became more prevalent in adults.
Discussion
The TOSCA natural history study represents the largest
clinical collection of TSC data to date. It is not possible
to derive an accurate absolute prevalence of TSC or its
individual manifestations in the general population from
this dataset because it was ascertained from a specialist
clinic population. However, the data do record the rela-
tive prevalence of different manifestations within this
cohort and their natural history. Reassuringly, our data
shows a number of similarities to what has been
reported in previous studies of TSC [1, 14]. For instance,
TSC2 mutations were more common than TSC1 muta-
tions [4, 15] and the prevalence of certain disease fea-
tures such as cortical tubers, subependymal nodules and
epilepsy were similar to previous reports [1, 14]. How-
ever, the frequencies of some of the other features such
as SEGA, TAND, and renal angiomyolipomas differed
from the published data [1, 14]. Potential reasons for
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these similarities and differences are discussed in more
details below.
SEGAs were reported in 24.4% of the patients, which
is much higher than the previously reported rate of 10–
15% [1, 11]. The higher frequency of SEGAs seen in this
cohort could be because the majority of centers included
in TOSCA were specialist neurology centers. There also
is ongoing discussion with respect to the most accurate
definition of SEGA, which may have been of influence
on the number of SEGA reported in TOSCA. In 2012, a
European Consensus Group defined SEGA as a tumor in
a TSC patient that is usually characterized by a location
near the foramen of Monro, > 0.5 cm in diameter, with
any documented growth, and gadolinium enhancement
on neuroimaging [16]. Later that year, an international
panel of experts defined SEGA as a lesion at the cau-
dothalamic groove with either a size of more than 1 cm
in any direction or a subependymal lesion at any loca-
tion that has shown serial growth on consecutive
imaging regardless of size [17]. Most SEGAs show avid
enhancement after contrast administration; however, a
growing subependymal lesion even in the absence of
enhancement should be considered a SEGA [17].
Median age at SEGA diagnosis was 8 years but more
than a quarter of patients were diagnosed with SEGA
already before age two years, highlighting the young age
at onset and early need for follow-up. When compared
to the last scan, 36.7% of ongoing SEGAs were reported
to have grown in size. Since SEGAs are known to grow
over time, there are existing recommendations for their
regular follow-up and timely management [10, 16].
Median time between scans was 1 year and median time
between SEGA diagnosis and start of treatment was less
than 1 year, reflecting good clinical practice with respect
to SEGA follow-up and management in the TOSCA
cohort. Although SEGA growth was most common
between ages 5–18 years, growth after age 18 years
remains possible as was shown in this cohort. This high-
lights the necessity to stay vigilant to possible symptoms
related to SEGA-growth also at adult age. In this ana-
lysis, surgery was the most common mode of treatment
for SEGAs followed by mTOR inhibitors. Until the re-
cent approval of everolimus for the treatment of SEGAs
associated with TSC [9, 18], surgery was the only treat-
ment option. For acutely symptomatic SEGAs, surgery
and cerebrospinal fluid diversion remain the treatment
of choice [10]. However, for asymptomatic growing
SEGAs, mTOR inhibitors may be considered especially
in multisystem disease [10], since mTOR inhibitors have
also been found to benefit other manifestations of TSC
[19–23]. Due to high rate of regrowth of residual tumors
[24], mTOR inhibitors should be recommended for
Fig. 4 Major manifestations of TSC categorized by age range in TOSCA participants (N = 2093). LAM, Lymphangioleiomyomatosis; SEGA,
subependymal giant cell astrocytoma; SEN, subependymal nodule; TOSCA, TuberOus SClerosis registry to increase disease Awareness; TSC,
tuberous sclerosis complex. *Percentage of the manifestation in each age category is calculated based on the total number of patients
under the respective age group
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those patients with SEGA, in whom total surgical re-
moval of SEGA is not possible. Complete SEGA resec-
tion might be more difficult to achieve in the presence
of bilateral SEGA [17], which were present in over one
third of patients in this cohort.
Similar to previous reports [3], this analysis of
TOSCA data showed that epilepsy (83.5%) was the
most commonly reported clinical presentation of
TSC. Focal seizures were the most common type of
seizures followed by infantile spasms. GABAergics
(vigabatrin) were most frequently used, both for focal
seizures and for infantile spasms. This finding is in
line with European recommendations made by TSC
Consensus meeting for SEGA and epilepsy manage-
ment in 2012, which recommended vigabatrin both
for infantile spasms and focal seizures in infants in
the first year of life [25]. Also the guidelines from the
2012 International TSC consensus Conference recom-
mend vigabatrin as first line and adrenocorticotropic
hormone as the second line treatment for infantile
spasms in individuals with TSC [10]. The use of other
anti-epileptic drugs; e.g., sodium channel blockers and
fructose derivatives will be described in more detail
in a subsequent paper. Despite a high rate of refrac-
tory epilepsy, alternative treatment options such as
the ketogenic diet and epilepsy surgery were not com-
monly used in this population.
Recently, mTOR inhibitors have been thought to be
useful for the treatment of refractory seizures [26–28].
Results from a phase III, randomized, double-blind,
placebo-controlled study (EXIST-3; NCT01713946)
could tell us the efficacy and safety of 2 trough-ranges of
everolimus (an mTOR inhibitor) as adjunctive therapy
in patients with TSC who have refractory seizures.
The TAND domain showed lower rates of behav-
ioral and psychiatric disorders than previously re-
ported [29–31]. The rates of intellectual disability
were similar to previous reports [29, 30] but there
was no clear evidence of a bimodal distribution of
IQ/DQ. Very high rates of academic difficulties and
of neuropsychological deficits were reported, and rep-
resent the first report of the potential magnitude of
academic and neuropsychological deficits in TSC.
Strikingly though, diagnoses of ASD, ADHD, anxiety
and depression were made very late, and the TAND
domain was characterized by very high rates of miss-
ing data. These findings suggest that, even in the
TOSCA cohort, TAND is underdiagnosed and there-
fore undertreated. A major challenge in maintaining a
database like TOSCA is to ensure that data are
complete, especially since these are collected from
many centers over a long time period. Missing data
for TAND suggests that a considerable number of pa-
tients were never assessed for TAND. It is apparent
that there is a specific need to educate clinicians to
assess all the patients with TSC for TAND. In order
to address the need, to increase the awareness of
TAND and the importance of screening for these
difficulties, the Neuropsychiatry Panel at the 2012
Tuberous Sclerosis Complex International Consensus
Conference developed a simple tool called the TAND
checklist [31, 32]. The neuropsychiatry panel recom-
mended at least an annual screening for TAND and
comprehensive formal evaluation for TAND at key
developmental time points: infancy (0–3 years), pre-
school (3–6 years), pre-middle school (6–9 years),
adolescence (12–16 years), early adulthood (18–25
years), and as needed thereafter. Management strat-
egies should be based on the TAND profile of each
patient and should be based on evidence-based good
practice guidelines/practice parameters for individual
disorders (e.g., autism spectrum disorder, attention
deficit hyperactivity disorder, anxiety disorder). The
TAND checklist can serve as an ideal guide to facili-
tate the discussion between the healthcare profes-
sionals and patients [31].
The lower rate of renal angiomyolipomas reported
in this population was likely attributable to the fact
that the cohort had a younger median age. This is
clear from Fig. 4 that the prevalence in adults (e.g.,
80% in age > 40) is the same as in other studies. Also,
the lower than expected prevalence of complications
of angiomyolipoma such as hypertension, microscopic
hematuria, and impaired renal function (reported in
the literature as 27, 25–50, and 40% respectively)
[33–35] reported here is a reflection of the young age
of this cohort, who have not had time to develop the
most common adult renal complications; and to good
practice in specialist clinics of active surveillance and
pre-emptive treatment of enlarging angiomyolipomas.
The finding that 27.8% of those with angiomyolipo-
mas had received treatment for them (presumably
mostly pre-emptive) supports this suggestion. An im-
portant finding is that a significant number of chil-
dren (55 patients aged <18 years) needed intervention
for their angiomyolipomas. It is also of note that the
occurrence of angiomyolipomas was not statistically
different in women compared to men. A previous re-
port [36] found angiomyolipomas complications were
more common in women than men, and two thirds
of the recruits for EXIST-2 [8] were women; both
findings implying that if there is no sex difference in
angiomyolipomas prevalence, women are more vulner-
able to developing complications. Renal angiomyolipo-
mas can cause considerable morbidity including
complications like aneurysm and hemorrhage [37].
Moreover, renal complications have been associated
with the most common cause for death in adult
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patients with TSC [38]. Timely diagnosis and treat-
ment are therefore of utmost importance. The main
objective in treating renal angiomyolipomas is to
prevent hemorrhage and to preserve renal function.
TSC Consensus Conference guidelines recommend
embolization followed by corticosteroids as the first-
line of treatment for angiomyolipomas presenting
with acute hemorrhage [10]. An mTOR inhibitor is
the recommended first-line therapy for asymptomatic,
growing angiomyolipoma > 3 cm in diameter [10]. In
this cohort, renal angiomyolipomas were most com-
monly treated with embolization followed by mTOR
inhibitors.
LAM is the main pulmonary manifestation of TSC,
which is seen in about 40% of women of reproductive
age [39, 40]. A recent study has reported a higher preva-
lence (up to 80%), especially in women over 40 years of
age [39]. In this dataset, LAM was reported much less
frequently compared to what has been published in
literature. This could probably be explained partly by the
young average age of the cohort and probably also
because screening may have been based on clinical
symptoms rather than high-resolution chest computed
tomography (HRCT). However 40% of these patients
were symptomatic from their LAM. Cudzilo et al. re-
ported that most women with TSC develop cystic
changes consistent with LAM [39], highlighting the im-
portance of routine surveillance using CT scan. As per
the guidelines, baseline pulmonary function testing and
HRCT must be performed in females 18 years or older,
even if asymptomatic [10]. Screening for LAM in female
patients and adult males (symptomatic) with TSC as per
the recommendations would be helpful. The high occur-
rence of symptomatic retinal hamartomas (12.6%) is a
new finding and has implications for surveillance. In this
analysis of TOSCA, it was also noted that most of the
patients were asymptomatic. It is therefore crucial to
highlight the importance of regular surveillance in all
patients with TSC even in the absence of symptoms to
help prevent complications.
With regard to the age at occurrence, most of the
manifestations in majority of the patients were diag-
nosed at the median age of 1 year. The mean age at
diagnosis for cardiac rhabdomyoma was 3.1 years.
The highest incidence of cardiac tumors is in children
below 2 years of age reaching up to 65–80% [40].
This late age at diagnosis of cardiac rhabdomyomas
could be related to age at diagnosis of TSC. Apart
from those diagnosed with rhabdomyomas on fetal
ultrasonography, other patients may have had an
echocardiogram organized after their diagnosis of
TSC was made.
Early, sometimes prenatal, diagnosis of TSC en-
ables the beginning of surveillance and thus
prevention or amelioration of complications such as
epilepsy, intellectual disability, autistic behaviors and
tumors development [17, 41, 42]. As TSC is a gen-
etic disease, the family members must also be
assessed. Family counselling must be done and gen-
etic testing carried out [10]. Current molecular tech-
niques enable the TSC1/TSC2 mutation detection in
more than 95% of patients [4]. In TOSCA partici-
pants, genetic testing was not reported in about 40%
of the patients, which might be due to ethical or
financial reasons. Five patients reported both TSC1
and TSC2 mutations, this unexpected finding is be-
ing investigated and will be reported in more detail
in future publications.
Though TOSCA is a large clinical case series, it
must be noted that patients were recruited through
clinical centers with expertise in TSC and milder
cases may not always be seen at these centers. The
study design therefore includes potential limitations
inherent to clinical case series, albeit large-scale,
multinational ones. Nevertheless, participation of a
large number of centers with complementary expert-
ise has helped inclusion of a huge number of patients
with TSC, which reveals occurrence rates of compli-
cations that are likely to be representative of hospital
clinical practice. This baseline paper of TOSCA pro-
vides a detailed description of the disease trajectory
of TSC. The registry can provide valuable insights
into the necessity for monitoring, the timing, and the
indications for treatment of this disease. Further
follow-up studies of TOSCA including research pro-
jects will provide more detail in understanding the
treatment interventions and outcomes.
Conclusion
This international registry provides a better under-
standing of the TSC manifestations, and facilitates de-
velopment of better management and surveillance
strategies for patients with TSC. Following patients
over the years will help in understanding any changes
in the treatment and outcome of the different mani-
festations. Baseline analysis has highlighted the ser-
ious import of epilepsy and SEGA in children, and
renal angiomyolipomas in children as well as adults.
We found inadequate surveillance for TAND; hope-
fully this will be improved in future by widespread
adoption of the international guidelines including use
of the TAND checklist. Clinicians need to be alert for
rare complications but especially changes in retinal
hamartomas. We believe comprehensive surveillance
will lead to more pro-active pre-emptive treatment
and better outcomes in future. Subsequent analyses
are planned yearly to allow the clinical course of the
disease over time to be evaluated.
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